<p><em>在交易完成时收到了 3.5 亿美元的预付款；总收益可达 4.25 亿美元，包括近期的业绩奖励支付</em></p>
<p><em>在交易完成时，资产负债表上约有 5.5 亿美元的现金及现金等价物，不包括潜在的未来业绩奖励，以支持非有机增长战略</em></p>
<p><em>持续运营预计将在 2026 年实现正向调整后息税折旧摊销前利润（EBITDA）</em></p>
<p>马萨诸塞州波士顿，2026 年 1 月 30 日（全球新闻稿）——Standard BioTools Inc.（纳斯达克：LAB）（“公司” 或 “Standard BioTools”）今天宣布已完成之前宣布的将 SomaLogic 出售给 Illumina, Inc.（纳斯达克：ILMN）（“Illumina”）的交易，交易金额为 3.5 亿美元的预付款和最多 7500 万美元的近期业绩奖励支付，总现金对价可达 4.25 亿美元，加上特定的版税。</p>
<p>“此次交易的完成标志着我们战略转型的重要里程碑。我们精简、高效且极具竞争力，今天的我们比昨天更强大，” Standard BioTools 的总裁兼首席执行官 Michael Egholm 博士表示。“我们现在在财务上有资源追求有纪律的并购，以加速增长和规模，这是我们行业中少数同类公司能够做到的。”</p>
<p><strong>交易详情</strong></p>
<p>通过将 SomaLogic 出售给 Illumina，包括 SomaScan®检测服务、授权站点和 KREX™，Standard BioTools 收到了 3.5 亿美元的预付款，需进行惯例调整，并有资格获得最多 7500 万美元的业绩奖励支付，其中包括基于 2025 年业绩的最多 2500 万美元和基于 2026 年业绩的最多 5000 万美元，支付条件是达到从 SOMAmer 基础的检测服务和相关产品产生的净收入的特定目标。1</p>
<p>Standard BioTools 还将获得基于 SOMAmer 的 NGS 文库制备试剂盒销售产生的净收入的 2% 版税，持续 10 年，并获得与单一 SOMAmer 在单重亲和检测中的商业化相关的知识产权的共同独占许可。</p>
<p>在交易完成后，截至 2026 年 1 月 30 日，Standard BioTools 预计现金及现金等价物余额约为 5.5 亿美元。该现金及现金等价物余额未经审计，可能会因完成财务结算程序和内部审查等原因而进行调整。该财务信息并不代表公司当前财务结果的全面声明。</p>
<p><strong>前瞻性声明</strong></p>
<p>本通讯包含 1995 年《私人证券诉讼改革法案》所定义的前瞻性声明，包括但不限于关于未来财务和业务表现的声明，包括潜在的业绩奖励支付和版税流；预期的现金及现金等价物；运营和战略计划；资本部署；市场和增长机会及潜力；以及实现交易预期收益的潜力。除历史事实声明外，所有声明均可能为前瞻性声明。这些前瞻性声明可能伴随有 “预期”、“相信”、“估计”、“期望”、“预测”、“打算”、“可能”、“计划”、“潜在”、“项目”、“目标”、“应该”、“可能”、“将” 等类似含义的词语和术语。</p>
<p>前瞻性声明受到众多风险和不确定性的影响，这些风险和不确定性可能导致实际结果与当前预期结果存在重大差异，包括但不限于：与交易相关的股东诉讼风险，包括由此产生的费用，预期交易的收益和机会可能无法实现或实现的时间可能比预期更长；先前和潜在未来收购的预期收益和协同效应以及任何此类业务的整合风险，包括此类交易可能推动长期盈利增长的潜力可能无法完全实现或实现的时间可能比预期更长；公司可能无法从此类交易中实现预期的成本节约；由于此类交易导致的整合、重组和过渡相关的干扰，包括客户、供应商和员工的流失，以及对公司开发活动和经营结果的不利影响；整合和重组活动，包括客户和员工关系、管理分心和运营表现下降；内部和外部持续和计划活动所需的成本可能高于预期，这可能导致公司比预期更快地使用现金，或改变或缩减公司的某些计划，或两者兼而有之；公司对费用、现金使用和现金需求的预期可能因计划变化或实际事件与我们的假设不同而被证明不正确；公司业务或外部市场条件的变化；预期的 NIH 资金压力；美国出口管制的预期影响和关税的预期影响；开发、制造、推出、营销和销售新产品固有的挑战；公司产品的组件或材料供应中断或延迟；依赖于资本设备销售占每季度收入的显著比例；客户运营的季节性变化；成本或费用的意外增加；持续或持续的预算、通货膨胀或衰退压力；合同关系的不确定性；客户减少研发支出或预算优先级变化；与公司研发活动和分销计划及能力相关的不确定性；潜在的产品性能和质量问题；与国际业务相关的风险；知识产权风险；以及竞争。</p>
<p>有关其他相关风险的信息，请参见公司于 2025 年 3 月 11 日向 SEC 提交的截至 2024 年 12 月 31 日的年度报告 10-K 中的 “风险因素” 部分，以及公司于 2025 年 8 月 15 日向 SEC 提交的截至 2025 年 6 月 30 日的季度报告 10-Q 和公司向 SEC 提交的其他文件。</p>
<p>这些前瞻性声明仅在本日期有效。公司不承担更新这些前瞻性声明的任何义务，除非法律要求。</p>
<p><strong>关于 Standard BioTools Inc.</strong></p>
<p>Standard BioTools Inc.（纳斯达克：LAB）拥有一系列成熟的、标准化的下一代技术，帮助生物医学研究人员更快地开发更好的药物。作为领先的解决方案提供商，该公司利用其专有的质量细胞术和微流体技术，提供可靠且可重复的健康和疾病洞察，帮助将科学发现转化为更好的患者结果。Standard BioTools 与全球领先的学术界、政府、制药、生物技术、植物和动物研究及临床实验室合作，专注于转化和临床研究中最紧迫的需求，包括肿瘤学、免疫学和免疫治疗。了解更多信息，请访问 standardbio.com 或在 X、Facebook®、LinkedIn 和 YouTube™上与我们联系。</p>
<p>仅供研究使用。不得用于诊断程序。</p>
<p>有限使用标签许可和其他条款可能适用：standardbio.com/legal/salesterms。</p>
<p>专利和许可信息：standardbio.com/legal/notices。</p>
<p>商标：standardbio.com/legal/trademarks。其他任何商标均为其各自所有者的唯一财产。©2026 Standard BioTools Inc.（前称 Fluidigm Corporation）。保留所有权利。</p>
<p><strong>投资者联系：</strong></p>
<p>ir@standardbio.com</p>
<p>1 基于 2025 年业绩的最高 2500 万美元的收益支付将根据最终交易文件的条款确定，包括 Standard BioTools 与 Illumina 之间的惯例审查程序。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5UZzFOaU0zTkRBd05USTFJekl3TURNNE1UZz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5UZzFOaU0zTkRBd05USTFJekl3TURNNE1UZz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTczOGFjMWQtNTY4NC00NmJmLWJlZjEtNjc5ZGZkYWJkNTVlLTEwMTUzOTEtMjAyNi0wMS0zMC1lbg==/tiny/Standard-BioTools-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTczOGFjMWQtNTY4NC00NmJmLWJlZjEtNjc5ZGZkYWJkNTVlLTEwMTUzOTEtMjAyNi0wMS0zMC1lbg==/tiny/Standard-BioTools-Inc-.png"/></p>

ILMN

SLGC

<p>Standard BioTools 已完成以 3.5 亿美元的现金出售 SomaLogic 给 Illumina，潜在总收益可达 4.25 亿美元，包括业绩奖励。该公司目前持有约 5.5 亿美元的现金及现金等价物，为未来通过并购实现增长奠定了基础。首席执行官 Michael Egholm 强调了此次交易带来的战略转型和财务实力，包括与 SOMAmer 技术相关的特许权使用费和共同独占许可。公司预计到 2026 年将实现正向调整后 EBITDA</p>

<p><em>Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments</em></p>
<div class="lb-trans"><p><em>在交易完成时收到了 3.5 亿美元的预付款；总收益可达 4.25 亿美元，包括近期的业绩奖励支付</em></p>
</div><p><em>Approximately $550 Million in cash &amp; cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy</em></p>
<div class="lb-trans"><p><em>在交易完成时，资产负债表上约有 5.5 亿美元的现金及现金等价物，不包括潜在的未来业绩奖励，以支持非有机增长战略</em></p>
</div><p><em>Continuing Operations on track to achieve positive adjusted EBITDA in 2026</em></p>
<div class="lb-trans"><p><em>持续运营预计将在 2026 年实现正向调整后息税折旧摊销前利润（EBITDA）</em></p>
</div><p>BOSTON, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced it has completed the previously announced sale of SomaLogic to Illumina, Inc. (NASDAQ: ILMN) (“Illumina”) for $350 million in upfront cash and up to $75 million in near-term earnout payments for aggregate cash consideration of up to $425 million plus specified royalties.</p>
<div class="lb-trans"><p>马萨诸塞州波士顿，2026 年 1 月 30 日（全球新闻稿）——Standard BioTools Inc.（纳斯达克：LAB）（“公司” 或 “Standard BioTools”）今天宣布已完成之前宣布的将 SomaLogic 出售给 Illumina, Inc.（纳斯达克：ILMN）（“Illumina”）的交易，交易金额为 3.5 亿美元的预付款和最多 7500 万美元的近期业绩奖励支付，总现金对价可达 4.25 亿美元，加上特定的版税。</p>
</div><p>“The closing of this transaction marks a major milestone in our strategic transformation. We are lean, focused and extremely well positioned, and emerge today far stronger than we were yesterday,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “We are now financially resourced to pursue disciplined M&amp;A that accelerates growth and scale like few similarly sized peers in our industry can.”</p>
<div class="lb-trans"><p>“此次交易的完成标志着我们战略转型的重要里程碑。我们精简、高效且极具竞争力，今天的我们比昨天更强大，” Standard BioTools 的总裁兼首席执行官 Michael Egholm 博士表示。“我们现在在财务上有资源追求有纪律的并购，以加速增长和规模，这是我们行业中少数同类公司能够做到的。”</p>
</div><p><strong>Transaction Details</strong></p>
<div class="lb-trans"><p><strong>交易详情</strong></p>
</div><p>With the sale of SomaLogic to Illumina, which includes SomaScan® Assay Services, Authorized Sites and KREX™, Standard BioTools received an upfront payment of $350 million, subject to customary adjustments, and is eligible to receive up to $75 million in earnout payments, consisting of up to $25 million based on 2025 performance and up to $50 million based on 2026 performance, payable upon the achievement of specified targets for net revenue generated from SOMAmer-based assay services and related products.1</p>
<div class="lb-trans"><p>通过将 SomaLogic 出售给 Illumina，包括 SomaScan®检测服务、授权站点和 KREX™，Standard BioTools 收到了 3.5 亿美元的预付款，需进行惯例调整，并有资格获得最多 7500 万美元的业绩奖励支付，其中包括基于 2025 年业绩的最多 2500 万美元和基于 2026 年业绩的最多 5000 万美元，支付条件是达到从 SOMAmer 基础的检测服务和相关产品产生的净收入的特定目标。1</p>
</div><p>Standard BioTools will also receive a 2% royalty on net revenues generated from sales of SOMAmer-based NGS library preparation kits for 10 years and a co-exclusive license to the intellectual property relating to Single SOMAmer commercialization in singleplex affinity assays.</p>
<div class="lb-trans"><p>Standard BioTools 还将获得基于 SOMAmer 的 NGS 文库制备试剂盒销售产生的净收入的 2% 版税，持续 10 年，并获得与单一 SOMAmer 在单重亲和检测中的商业化相关的知识产权的共同独占许可。</p>
</div><p>Following the closing of the transaction, as of January 30, 2026, Standard BioTools estimates a cash and cash equivalents balance of approximately $550 million. This approximate cash and cash equivalents balance is unaudited and may be adjusted as a result of, among other things, completion of financial closing procedures and internal reviews. This financial information does not represent a comprehensive statement of the Company’s current financial results.</p>
<div class="lb-trans"><p>在交易完成后，截至 2026 年 1 月 30 日，Standard BioTools 预计现金及现金等价物余额约为 5.5 亿美元。该现金及现金等价物余额未经审计，可能会因完成财务结算程序和内部审查等原因而进行调整。该财务信息并不代表公司当前财务结果的全面声明。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance, including with respect to potential earnout payments and royalty streams; expected cash and cash equivalents; operational and strategic plans; deployment of capital; market and growth opportunity and potential; and the potential to realize the expected benefits of the transaction. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning.</p>
<div class="lb-trans"><p>本通讯包含 1995 年《私人证券诉讼改革法案》所定义的前瞻性声明，包括但不限于关于未来财务和业务表现的声明，包括潜在的业绩奖励支付和版税流；预期的现金及现金等价物；运营和战略计划；资本部署；市场和增长机会及潜力；以及实现交易预期收益的潜力。除历史事实声明外，所有声明均可能为前瞻性声明。这些前瞻性声明可能伴随有 “预期”、“相信”、“估计”、“期望”、“预测”、“打算”、“可能”、“计划”、“潜在”、“项目”、“目标”、“应该”、“可能”、“将” 等类似含义的词语和术语。</p>
</div><p>Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to: risks of stockholder litigation relating to the transaction, including resulting expense the potential that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected; risks that the anticipated benefits and synergies of prior and potential future acquisitions and the integration of any such businesses, including the potential for such transactions to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from such transactions; possible integration, restructuring and transition-related disruption resulting from such transactions, including through the loss of customers, suppliers, and employees and adverse impacts on the Company’s development activities and results of operation; integration and restructuring activities, including customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company’s plans, or both; risks that the Company’s expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company’s business or external market conditions; anticipated NIH funding pressures; the expected effect from U.S. export controls and the expected impact from tariffs; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company’s products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company’s research and development activities and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition.</p>
<div class="lb-trans"><p>前瞻性声明受到众多风险和不确定性的影响，这些风险和不确定性可能导致实际结果与当前预期结果存在重大差异，包括但不限于：与交易相关的股东诉讼风险，包括由此产生的费用，预期交易的收益和机会可能无法实现或实现的时间可能比预期更长；先前和潜在未来收购的预期收益和协同效应以及任何此类业务的整合风险，包括此类交易可能推动长期盈利增长的潜力可能无法完全实现或实现的时间可能比预期更长；公司可能无法从此类交易中实现预期的成本节约；由于此类交易导致的整合、重组和过渡相关的干扰，包括客户、供应商和员工的流失，以及对公司开发活动和经营结果的不利影响；整合和重组活动，包括客户和员工关系、管理分心和运营表现下降；内部和外部持续和计划活动所需的成本可能高于预期，这可能导致公司比预期更快地使用现金，或改变或缩减公司的某些计划，或两者兼而有之；公司对费用、现金使用和现金需求的预期可能因计划变化或实际事件与我们的假设不同而被证明不正确；公司业务或外部市场条件的变化；预期的 NIH 资金压力；美国出口管制的预期影响和关税的预期影响；开发、制造、推出、营销和销售新产品固有的挑战；公司产品的组件或材料供应中断或延迟；依赖于资本设备销售占每季度收入的显著比例；客户运营的季节性变化；成本或费用的意外增加；持续或持续的预算、通货膨胀或衰退压力；合同关系的不确定性；客户减少研发支出或预算优先级变化；与公司研发活动和分销计划及能力相关的不确定性；潜在的产品性能和质量问题；与国际业务相关的风险；知识产权风险；以及竞争。</p>
</div><p>For information regarding other related risks, see the “Risk Factors” section in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 11, 2025, in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the SEC on August 15, 2025 and in the Company’s other filings with the SEC.</p>
<div class="lb-trans"><p>有关其他相关风险的信息，请参见公司于 2025 年 3 月 11 日向 SEC 提交的截至 2024 年 12 月 31 日的年度报告 10-K 中的 “风险因素” 部分，以及公司于 2025 年 8 月 15 日向 SEC 提交的截至 2025 年 6 月 30 日的季度报告 10-Q 和公司向 SEC 提交的其他文件。</p>
</div><p>These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.</p>
<div class="lb-trans"><p>这些前瞻性声明仅在本日期有效。公司不承担更新这些前瞻性声明的任何义务，除非法律要求。</p>
</div><p><strong>About Standard BioTools Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Standard BioTools Inc.</strong></p>
</div><p>Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.</p>
<div class="lb-trans"><p>Standard BioTools Inc.（纳斯达克：LAB）拥有一系列成熟的、标准化的下一代技术，帮助生物医学研究人员更快地开发更好的药物。作为领先的解决方案提供商，该公司利用其专有的质量细胞术和微流体技术，提供可靠且可重复的健康和疾病洞察，帮助将科学发现转化为更好的患者结果。Standard BioTools 与全球领先的学术界、政府、制药、生物技术、植物和动物研究及临床实验室合作，专注于转化和临床研究中最紧迫的需求，包括肿瘤学、免疫学和免疫治疗。了解更多信息，请访问 standardbio.com 或在 X、Facebook®、LinkedIn 和 YouTube™上与我们联系。</p>
</div><p>For Research Use Only. Not for use in diagnostic procedures.</p>
<div class="lb-trans"><p>仅供研究使用。不得用于诊断程序。</p>
</div><p>Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.</p>
<div class="lb-trans"><p>有限使用标签许可和其他条款可能适用：standardbio.com/legal/salesterms。</p>
</div><p>Patent and License Information: standardbio.com/legal/notices.</p>
<div class="lb-trans"><p>专利和许可信息：standardbio.com/legal/notices。</p>
</div><p>Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2026 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.</p>
<div class="lb-trans"><p>商标：standardbio.com/legal/trademarks。其他任何商标均为其各自所有者的唯一财产。©2026 Standard BioTools Inc.（前称 Fluidigm Corporation）。保留所有权利。</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>ir@standardbio.com</p>
<div class="lb-trans"><p>ir@standardbio.com</p>
</div><p>1 The earnout payment of up to $25 million based on 2025 performance will be determined in accordance with the terms of the definitive transaction documentation, including customary review procedures between Standard BioTools and Illumina.</p>
<div class="lb-trans"><p>1 基于 2025 年业绩的最高 2500 万美元的收益支付将根据最终交易文件的条款确定，包括 Standard BioTools 与 Illumina 之间的惯例审查程序。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5UZzFOaU0zTkRBd05USTFJekl3TURNNE1UZz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY0NTg1NiM3NDAwNTI1IzIwMDM4MTg="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTczOGFjMWQtNTY4NC00NmJmLWJlZjEtNjc5ZGZkYWJkNTVlLTEwMTUzOTEtMjAyNi0wMS0zMC1lbg==/tiny/Standard-BioTools-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZTczOGFjMWQtNTY4NC00NmJmLWJlZjEtNjc5ZGZkYWJkNTVlLTEwMTUzOTEtMjAyNi0wMS0zMC1lbg==/tiny/Standard-BioTools-Inc-.png"/></p>

Standard BioTools Completes Sale of SomaLogic to Illumina | LAB Stock News

Standard BioTools 完成了将 SomaLogic 出售给 Illumina 的交易 | LAB 股票新闻